| Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) (NCT05461430) | Travera Inc | 2022-07-15 |
| IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer (NCT04854590) | AstraZeneca | 2021-04-22 |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors (NCT04660929) | Carisma Therapeutics Inc | 2021-02-02 |
| M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers (NCT03554473) | National Cancer Institute (NCI) | 2018-09-11 |
| Comparable Study of Different Thoracic Radiotherapy Regimens for Extensive Stage Small Cell Lung Cancer (NCT02675088) | Chinese Academy of Medical Sciences | 2017-12-01 |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers (NCT03212404) | Checkpoint Therapeutics, Inc. | 2017-09-20 |
| A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens (NCT03092739) | Hoffmann-La Roche | 2017-05-03 |
| TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES) (NCT02608411) | Istituto Oncologico Veneto IRCCS | 2016-02-19 |
| Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC (NCT02688036) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2016-02-01 |
| Neurocognitive Function After Prophylactic Cranial Irradiation & Hippocampal Sparing in LD SCLC Patients - a Pilot Study (NCT02366741) | Sheba Medical Center | 2015-01-01 |
| Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma (NCT02034123) | GlaxoSmithKline | 2014-02-04 |
| Temozolomide as Maintenance Therapy in Small Cell Lung Cancer (NCT01900951) | Chinese PLA General Hospital | 2013-01-01 |
| Study of Arsenic Trioxide in Small Cell Lung Cancer (NCT01470248) | Emory University | 2011-08-01 |
| A Phase I Study of iPS Cell Generation From Patients With COPD (NCT01860898) | Mayo Clinic | 2009-09-01 |
| Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient (NCT00826644) | Chonnam National University Hospital | 2009-01-01 |
| A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide (NCT00537511) | Celgene | 2008-02-01 |
| BI 2536 Second Line Monotherapy in SCLC (NCT00412880) | Boehringer Ingelheim | 2007-02-14 |
| A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy (NCT00447421) | Eli Lilly and Company | 2007-02-01 |
| A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer (NCT00359359) | Bayer | 2006-07-01 |
| Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (NCT00305942) | SCRI Development Innovations, LLC | 2006-03-01 |
| Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer (NCT00294190) | SCRI Development Innovations, LLC | 2006-02-01 |
| Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer (NCT00129974) | Tufts Medical Center | 2005-08-01 |
| Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY) (NCT00324558) | Clinica Universidad de Navarra, Universidad de Navarra | 2005-06-01 |
| Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum (NCT00094978) | National Cancer Institute (NCI) | 2004-10-25 |
| A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned (NCT00191750) | Eli Lilly and Company | 2004-07-01 |
| Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy (NCT00100256) | Andarix Pharmaceuticals | 2004-01-01 |
| Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer (NCT00126828) | AHS Cancer Control Alberta | 2003-01-01 |
| Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer (NCT00046787) | Astellas Pharma Inc | 2002-09-01 |